Oxygen and the liberation of placental factors responsible for vascular compromise.
Maternal endothelial activation in pre-eclampsia is attributed to the release of unknown factors from a hypoperfused placenta. To further characterize these factors, we have used a serum-free placental villous explant culture model and investigated the effect of the liberated soluble factors produced on human endothelial cell cultures. Term placental villous explants from uncomplicated pregnancies were cultured for 4 days in 20, 6 or 1% O2 to mimic placental hyperoxia, normoxia and hypoxia. Medium collected from viable explants was applied to cultured human uterine microvascular endothelial cells. Medium conditioned by hypoxic explants caused a significant decrease in endothelial cell ATP levels and mitochondrial dehydrogenase activity, suggestive of a reduced metabolic rate. An additional reduction in mitochondrial membrane potential and increased endothelial cell death occurred as the oxygen concentration to which explants had been exposed decreased. Effects of the hypoxic explant medium were also seen ex vivo in a wire myography model of myometrial artery function, with increased vasoconstriction and attenuated vasodilation following exposure to hypoxic explant medium. These results suggest that hypoxia (1% O2) may stimulate the release of soluble factors from the placenta, which have an adverse effect on endothelial cell metabolism and mitochondrial integrity in vitro. These potentially pathogenic factors are now being characterized.
Robinson
Nicola J
NJ
Maternal and Fetal Health Research Group, School of Clinical and Laboratory Sciences, The University of Manchester, St Mary's Hospital, Manchester, UK. nicola.j.robinson@manchester.ac.uk
Wareing
Mark
M
Hudson
Nicola K
NK
Blankley
Richard T
RT
Baker
Philip N
PN
Aplin
John D
JD
Crocker
Ian P
IP
D017209:Apoptosis; D001127:Arginine Vasopressin / Q000494:pharmacology; D001562:Benzimidazoles / Q000378:metabolism; D001920:Bradykinin / Q000494:pharmacology; D002232:Carbocyanines / Q000378:metabolism; D002478:Cells, Cultured; D002824:Chorionic Villi / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000032:analysis / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology; D011464:Epoprostenol / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005562:Formazans / Q000378:metabolism; D006801:Humans; D018496:Hyperoxia / Q000503:physiopathology; D000860:Hypoxia / Q000503:physiopathology; D008564:Membrane Potentials; D008928:Mitochondria / Q000502:physiology; D009215:Myometrium / Q000098:blood supply; D009336:Necrosis; D018919:Neovascularization, Physiologic; D010100:Oxygen / Q000502:physiology*; D010920:Placenta / Q000166:cytology / Q000378:metabolism*; D011247:Pregnancy; D013778:Tetrazolium Salts / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
D001562:Benzimidazoles; D002232:Carbocyanines; D019332:Endothelin-1; D005562:Formazans; D013778:Tetrazolium Salts; D014665:Vasodilator Agents; D001127:Arginine Vasopressin; C068624:5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine; C079782:MTT formazan; D011464:Epoprostenol; D010100:Oxygen; D001920:Bradykinin